title: An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective.
abstract: Overactivation of calcium-activated neutral protease (calpain) has been implicated in the pathophysiology of several degenerative conditions, including stroke, myocardial ischemia, neuromuscular degeneration, and cataract formation. Alpha-mercaptoacrylate derivatives (exemplified by PD150606), with potent and selective inhibitory actions against calpain, have been identified. PD150606 exhibits the following characteristics: (i) Ki values for mu- and m-calpains of 0.21 microM and 0.37 microM, respectively, (ii) high specificity for calpains relative to other proteases, (iii) uncompetitive inhibition with respect to substrate, and (iv) it does not shield calpain against inactivation by the active-site inhibitor trans-(epoxysuccinyl)-L-leucyl-amido-3-methylbutane, suggesting a nonactive site action for PD150606. The recombinant calcium-binding domain from each of the large or small subunits of mu-calpain was found to interact with PD150606. In low micromolar range, PD15O6O6 inhibited calpain activity in two intact cell systems. The neuroprotective effects of this class of compound were also demonstrated by the ability of PD150606 to attenuate hypoxic/hypoglycemic injury to cerebrocortical neurons in culture and excitotoxic injury to Purkinje cells in cerebellar slices.
authors.affiliation: Department of Neuroscience Therapeutics, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA.
authors.forename: K K
authors.initials: KK
authors.lastname: Wang
authors.forename: R
authors.initials: R
authors.lastname: Nath
authors.forename: A
authors.initials: A
authors.lastname: Posner
authors.forename: K J
authors.initials: KJ
authors.lastname: Raser
authors.forename: M
authors.initials: M
authors.lastname: Buroker-Kilgore
authors.forename: I
authors.initials: I
authors.lastname: Hajimohammadreza
authors.forename: W
authors.initials: W
authors.lastname: Probert A
authors.forename: F W
authors.initials: FW
authors.lastname: Marcoux
authors.forename: Q
authors.initials: Q
authors.lastname: Ye
authors.forename: E
authors.initials: E
authors.lastname: Takano
authors.forename: M
authors.initials: M
authors.lastname: Hatanaka
authors.forename: M
authors.initials: M
authors.lastname: Maki
authors.forename: H
authors.initials: H
authors.lastname: Caner
authors.forename: J L
authors.initials: JL
authors.lastname: Collins
authors.forename: A
authors.initials: A
authors.lastname: Fergus
authors.forename: K S
authors.initials: KS
authors.lastname: Lee
authors.forename: E A
authors.initials: EA
authors.lastname: Lunney
authors.forename: S J
authors.initials: SJ
authors.lastname: Hays
authors.forename: P
authors.initials: P
authors.lastname: Yuen
mesh_terms: D000179:Acrylates / Q000494:pharmacology*; D000595:Amino Acid Sequence; D000818:Animals; D002118:Calcium / Q000378:metabolism; D015687:Cell Hypoxia; D002460:Cell Line; D002540:Cerebral Cortex / Q000166:cytology / Q000187:drug effects; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D006023:Glycoproteins / Q000494:pharmacology*; D007003:Hypoglycemia / Q000503:physiopathology; D066298:In Vitro Techniques; D008969:Molecular Sequence Data; D009474:Neurons / Q000187:drug effects; D018696:Neuroprotective Agents; D011689:Purkinje Cells / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000633:toxicity
chemical_list: D000179:Acrylates; D015853:Cysteine Proteinase Inhibitors; D006023:Glycoproteins; D018696:Neuroprotective Agents; C100442:PD 150606; C039304:calpain inhibitors; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; D002118:Calcium